Ibsan 75 mg (Tablet)
Unit Price: ৳ 5.00 (20's pack: ৳ 100.00)
Medicine Details
| Category | Details |
|---|---|
| Generic | Irbesartan |
| Company | Acme laboratories ltd |
| Also available as |
Indications
- Treatment of essential hypertension
- Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus
Pharmacology
- Angiotensin II receptor antagonist
- Blocks vasoconstricting and aldosterone-secreting effects of angiotensin II by binding to AT1 receptors
Dosage & Administration
- Usual recommended initial and maintenance dose is Irbesartan 150 mg once daily
- Can be taken with or without food
- Initiation of therapy with Irbesartan 75 mg could be considered in haemodialysed patients and in the elderly over 75 years
- In patients insufficiently controlled with Irbesartan 150 mg once daily, the dose can be increased to Irbesartan 300 mg
- Treatment of renal disease in hypertensive type 2 diabetic patients should be initiated at Irbesartan 150 mg once daily and titrated up to Irbesartan 300 mg once daily
- Dosage adjustment is not usually necessary for the elderly
- Irbesartan is not recommended for use in children and adolescents
Interaction
- Potential interaction with diuretics and other antihypertensive agents
- Caution advised with potassium supplements and potassium-sparing diuretics
- Possible reversible increases in serum lithium concentrations and toxicity when coadministered with lithium
- Potential attenuation of antihypertensive effect when administered with non-steroidal anti-inflammatory drugs
Contraindications
- Concomitant use with aliskiren in patients with diabetes and renal impairment (GFR <60 ml/min)
- Pregnancy
Side Effects
- Diarrhoea
- Fatigue
- Dyspepsia or heartburn
- Dizziness
- Orthostatic hypotension
- Nausea
- Vomiting
- Musculoskeletal pain
- Thrombocytopaenia
- Hyperkalaemia
- Elevated serum creatinine
Pregnancy & Lactation
- Contraindicated in the second and third trimesters of pregnancy
- Not recommended during lactation
- Precautions to prevent hypotension in lactating women
Precautions & Warnings
- Caution in patients with renal artery stenosis, depletion of intravascular volume, aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy
- Close monitoring of serum potassium in patients at risk of hyperkalaemia
- Special caution indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy
- Not recommended for patients with primary aldosteronism
- Caution in patients with severe congestive heart failure or underlying renal disease
- Caution to prevent excessive blood pressure decrease in patients with ischaemic cardiopathy or ischaemic cardiovascular disease
Use in Special Populations
- No dosage adjustment is necessary in patients with impaired renal function
- Lower starting dose of Ibsan 75 mg should be considered for patients undergoing haemodialysis
- No dosage adjustment is necessary in patients with mild to moderate hepatic impairment
- Effects may vary across different subgroups in hypertensive patients with type 2 diabetes and renal disease
- Close monitoring of serum potassium in patients at risk is recommended
- Special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy
Overdose Effects
- No specific toxicity reported in adults exposed to doses of up to 900 mg/day for 8 weeks
- Manifestations of overdosage may include hypotension and tachycardia
- Symptomatic and supportive treatment recommended in case of overdose
Therapeutic Class
- Angiotensin-ll receptor blocker
Storage Conditions
- Store in a cool and dry place
- Protected from light